Global Solid Tumor Testing Industry Trends: Where the Market Is Headed by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Solid Tumor Testing Market Size Likely To Evolve From 2025 Through 2034?

The solid tumor testing market has experienced robust expansion in recent years. Forecasts indicate it will expand from $27.96 billion in 2024 to $29.94 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 7.1%. Historically, this growth has been driven by factors such as the adoption of personalized or precision medicine, challenges in tumor-selective drug delivery, limited therapeutic efficacy, high unsustainable costs, and reductionist methods in cancer chemotherapies.

The solid tumor testing market is projected to experience substantial expansion over the upcoming years, with its size anticipated to reach $39.95 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.5%. This growth throughout the forecast period is primarily driven by the rising incidence of cancer, improvements in healthcare infrastructure, the advent of AI and IoT-driven diagnostic tools, and increasing government initiatives. Key trends identified for the forecast period encompass significant advancements in diagnostic technologies, the introduction of nanocarrier-based therapeutic approaches, various strategic collaborations, and the development of next-generation testing devices.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

Which Drivers Are Impacting The Solid Tumor Testing Market?

The expanding occurrence of cancer is anticipated to drive the solid tumor testing market’s future growth. Cancer is a condition characterized by the uncontrolled proliferation and dissemination of abnormal cells in the body. These malignant cells, known as cancer cells, can invade nearby tissues and organs, and may spread to other parts of the body through the bloodstream or lymphatic system. About 90% of adult cancers are solid tumors. Solid tumor testing is employed to detect cancer cells in the blood of patients with solid tumors, even when the cancer is not yet apparent on imaging tests. For example, a June 2023 report from the Centers for Disease Control and Prevention, a US-based national public health agency, stated that in 2020, there were 1,603,844 new cancer cases and 602,347 cancer-related deaths in the US, with 403 new cancer cases and 144 cancer-related deaths reported for every 100,000 people. Thus, the escalating prevalence of cancer is fueling the expansion of the solid tumor testing market.

What Are The Primary Types Of Segments Analyzed In The Solid Tumor Testing Market?

The solid tumor testingmarket covered in this report is segmented –

1) By Type: Genetic Testing; Conventional Testing

2) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Cervical Cancer

3) By Application: Clinical; Research

4) By End-Users: Hospitals; Pharmaceutical And Biotechnology Companies; Contract Research Organizations; Academic Research Institutions

Subsegments:

1) By Genetic Testing: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Fluorescence In Situ Hybridization (FISH)

2) By Conventional Testing: Histopathology; Cytology; Imaging Techniques

What Trends Are Redefining The Solid Tumor Testing Market Dynamics?

Innovative liquid biopsy test solutions represent a significant trend gaining traction in the solid tumor testing market. Major companies operating within this market are concentrating on developing advanced liquid biopsy test solutions to fortify their position and secure a competitive advantage. For instance, in June 2020, NeoGenomics Inc., a US-based testing laboratory company, launched its extensive collection of three solid tumor liquid biopsy tests for cancer patients. These cutting-edge tests are designed to identify cancer cells in the blood of individuals with solid tumors, even when the cancer is not yet visible through imaging. The tests can aid doctors in determining subsequent testing or treatment options. Additionally, they are non-invasive, facilitate early detection, enable personalized treatment, and hold FDA approval. Furthermore, these three new tests boast turnaround times of seven days or fewer, thereby saving clinicians a substantial amount of time.

Who Are The Top Performing Companies In The Solid Tumor Testing Market In Recent Years?

Major companies operating in the solid tumor testing market include Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company (BD), Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Novocure Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Eutropics Pharmaceuticals Inc., Anixa Biosciences Inc., Cellular Biomedicine Group.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

What Regional Growth Trends Are Shaping The Solid Tumor Testing Market Outlook?

North America was the largest region in the solid tumor testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Solid Tumor Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12658&type=smp

Browse Through More Reports Similar to the Global Solid Tumor Testing Market 2025, By The Business Research Company

Tumor Ablation Therapy Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report

Tumor Embolization Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

Testing Software Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/testing-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795